Skip to main content

Table 1 Notable clinical trials targeting immune checkpoints in hematological malignancies

From: Targeting immune checkpoints in hematological malignancies

Clinical trial Phase Patient characteristics Intervention Response Reference
NCT01592370 I Relapsed or refractory HL Nivolumab ORR 87% [46]
CheckMate 205 (NCT02181738) II cHLCohort A: brentuximab vedotin naïve
Cohort B: brentuximab vedotin after auto-HCT
Cohort C: brentuximab vedotin before and/or after auto-HCT
Cohort D: nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine for newly diagnosed HL
Nivolumab ORR:
Cohort A 65%
Cohort B 68%
Cohort C 73%
Cohort D 84%
[47, 48]
KEYNOTE-013 (NCT01953692) I cHL after brentuximab vedotin failure Pembrolizumab ORR 65% [49]
KEYNOTE-087 (NCT02453594) II Relapsed or refractory cHL,
Cohort 1: after ASCT/brentuximab vedotin
Cohort 2: ineligible for ASCT and experienced treatment failure with brentuximab vedotin
Cohort 3: No brentuximab vedotin after ASCT
Pembrolizumab ORR:
Cohort 1 73.9%
Cohort 2 64.2%
Cohort 3 70%
[50]
NCT02038933 II Relapsed or refractory DLBCL
Cohort 1: auto-HCT-failed
Cohort 2: auto-HCT-ineligible
Nivolumab ORR:
Cohort 1 10%
Cohort 2 3%
[51]
NCT02446457 II Relapsed FL Pembrolizumab
Rituximab
Pre-planned interim analysis: ORR 80% [52]
NCT03245021 II Previously untreated FL Single-agent nivolumab followed by combined nivolumab and rituximab Pre-planned interim analysis: ORR 84% [53]
NCT03278782 I/II Relapsed or refractory peripheral T cell lymphoma (PTCL) Pembrolizumab
Romidepsin
ORR 44% [54]
NCT02243579 II Recurrent mycosis fungoides and Sezary syndrome Pembrolizumab ORR 38% [55]
KEYNOTE-023 (NCT02036502) I Relapsed or refractory MM Pembrolizumab combined with lenalidomide and low-dose dexamethasone ORR 44% [56]
KEYNOTE-183 (NCT02576977) III Relapsed or refractory MM Pembrolizumab plus pomalidomide and dexamethasone Pembrolizumab plus pomalidomide and dexamethasone group:
Median PFS: 5.6 months (95% CI 3.7–7.5);
Pomalidomide and dexamethasone group: 8.4 months (5.9–not reached)
[57]
KEYNOTE-185 (NCT02579863) III Treatment-naive MM Pembrolizumab plus lenalidomide and dexamethasone Progression-free survival estimates at 6-months were 82.0% (95% CI 73.2–88.1) versus 85.0% (76.8–90.5; hazard ratio [HR] 1.22; 95% CI 0.67–2.22; p = 0.75) [58]
NCT01822509 I Patients with relapse after allogeneic transplantation:
AML (in 12 patients, including 3 with leukemia cutis and 1 with a myeloid sarcoma), HL (in 7), NHL (in 4), and myelodysplastic syndrome (in 2). One patient each had MM, myeloproliferative neoplasm, and acute lymphoblastic leukemia
Ipilimumab Patients that received a dose of 10 mg/kg: CR (23%) [59]
NCT02397720 II Relapsed or refractory AML Azacitidine and nivolumab ORR 33% [60]
  1. cHL classic Hodgkin lymphoma, NHL non-Hodgkin’s lymphoma, PTCL peripheral T cell lymphoma, MM multiple myeloma, AML acute myeloid leukemia, ASCT allogeneic stem cell transplantation, HCT hematopoietic cell transplantation, ORR objective response rate, CR complete response, HR hazard ratio, PFS progression-free survival, FL follicular lymphoma, DLBCL diffuse large B cell lymphoma